About US
Contact us
-
Emgality maker Lilly courts payers with new migraine ER dataSales of Eli Lilly’s migraine and cluster headache med Emgalityhave lagged behind competitors from Amgen and Novartis and Teva Pharmaceutical. And in its push to bring payers on board, Lilly is deplo2019/7/15
-
Gilead snags Lilly exec Shaw for Kite CEO positionBack in May, new Gilead Sciences CEO Daniel O’Day said he’d be looking for a CEO for Gilead’s Kite unit. And he’s found his pick. Thursday, the Big Biotech said it wouldbring onEli Lilly executive Ch2019/7/12
-
Indivior's former parent ponies up a whopping $1.4B to settle Suboxone marketing probeWith the feds sniffing around Indivior’s aggressive marketing of its opioid addiction treatment Suboxone, the forecast looked bleak for the drugmaker. The stink was bad enough that Indivior’s former2019/7/12
-
Pharma Alnylam recruits former Shire exec to replace departing CFO SoniIt’s been less than two years since former Shire CFO Jeff Poulton left the biopharma world, but he’s back—and he’s landed at Alnylam. In replacing current financial chief Manmeet Soni, Poulton will h2019/7/11
-
Lilly Bio-Medicines chief Christi Shaw steps aside, leaving key launches behindEarly into an important launch for Emgality and amid rollouts for other key meds, Eli Lilly Bio-Medicines chief Christi Shaw is stepping aside. Shaw will workwith the drugmaker through the end2019/7/11
-
Sorry, pharma: White House pulls industry's favored rebate proposalWhen the Trump administration rolled out its proposal to dramatically reshape drug rebates last year, the pharma industry cheered. Analysts figured the move wouldspread to private plans, too.2019/7/10
-
The hits keep coming: Apotex loses 31 drug approvals after FDA cites plants for 'inadequate' controlsIt’s been a troubled few years for Canadian generics maker Apotex after the unsolved murder of founder Barry Sherman and a possible sale in the works. Now, aftermultiple warnings from the FDA, Apotex2019/7/10
-
FDA promises 'elevated' new drug approvals, but warns of potential pitfalls: reportThe FDA has approved 14 new drugs so far this year, lagging behind the 20 approvals it had charted by this time last year. Is it a sign that the FDA is becoming more cautious in the wake of Scott Got2019/7/9
-
Novartis amps up Symjepi launch to fill Pfizer's EpiPen supply gapMylan and its EpiPen manufacturing partner Pfizer have had trouble keeping up with demand. That's not good news as the key back-to-school season nears. Except, perhaps, for Novartis' Sandoz un2019/7/9
-
Bayer floats animal health merger with Lilly spinoff Elanco: reportBayer’s for-sale animal health unit has been stirring up interest among private equity players—but the German pharma may have another buyer in mind. The company has approached Elanco, spun off by Eli2019/7/8